UMass Amherst researchers have developed a groundbreaking nanoparticle-based cancer vaccine that prevented melanoma, pancreatic, and triple-negative breast cancers in mice—with up to 88% remaining tumor-free. The vaccine triggers a multi-pathway immune response, producing powerful T-cell activation and long-term immune memory that stops both tumor growth and metastasis. By combining cancer-specific antigens with a lipid nanoparticle “super adjuvant,” it overcomes key challenges in cancer immunotherapy.